Boston Scientific has received CE Mark approval for use of the GUIDE DBS System, a deep brain stimulation (DBS) visual simulation system.
GUIDE DBS offers clinicians with 3D visualization information that simulates stimulation output, which may enable more precise targeting of therapy and reduce programming time.
GUIDE DBS helps in visualizing the relative position of lead location and then utilize stimulation field models within the brain.
University Clinic Wurzburg Germany Department of Neurology director Jens Volkmann said, "The visualization of the stimulation fields is designed to improve therapy because physicians may take advantage of the unique programming options of the Vercise DBS System."
Combined with the Vercise DBS System, the GUIDE DBS technology provides advanced deep brain stimulation technology to neurologists, neurosurgeons and their patients.
Boston Scientific Neuromodulation division president Maulik Nanavaty said, "This innovative system is the first of its kind and designed to help physicians provide better therapy for their patients and improve programming time."
GUIDE DBS is the first commercial product resulting from the Boston Scientific acquisition of Intelect Medical in 2011.
GUIDE DBS and the Vercise DBS System are CE Marked for the treatment of Parkinson's disease. The Vercise DBS System was approved for sale in Europe in 2012. In US, both these systems are investigational and not available for sale.
According to the European Parkinson's Disease Association, Parkinson's disease is a progressive neurological disorder which affects 6.3 million people worldwide.
